Figure 6.

AAV vectorized expression of 3TSR, Fc3TSR and Bevacizumab increases survival in the ID8 mouse model of advanced stage epithelial ovarian carcinoma. (A) 64 mice were injected with 1 × 10⁶ ID8 ovarian epithelial carcinoma cells into the ovarian bursa. Forty days later, groups of mice (n = 8) were i.m. administered AAV-3TSR (1 × 10¹¹ vg), Fc3TSR (1 × 10¹¹ vg) or AAV-Bevacizumab (1 × 10¹⁰ vg) followed 20 days later by i.v administration of 1 × 10⁸ PFU AOaV-1. Mice were monitored daily for signs of ruffled fur, hunching, reduction in movement, and body score. Ascites was drained ~1 time per week as needed. The survival curve from panel A was separated into subcategories to facilitate comparisons of the gene therapies alone and in combination with AOaV-1. Statistics adjacent to the figure legends denote statistical significance between the specific treatment and PBS. (B) Monotherapies. (C) Combination therapies. (D) AAV-3TSR. (E) Fc3TSR. (F) AAV-Bevacizumab. AOaV-1, avian orthoavulavirus-1; AAV, Adeno-associated virus; PBS, phosphate-buffered saline mock control group; 3TSR, thrombospondin-1 type I repeats; * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significant.